ABG
VRDN icon

Ally Bridge Group’s Viridian Therapeutics VRDN Stock Holding History

Ally Bridge Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-201,752
Closed -$4.8M – 22
2023
Q2 		$4.8M Buy
+201,752
New +$5.17M 5.81% 7
2022
Q3 		– Sell
-496,012
Closed -$5.74M – 46
2022
Q2 		$5.74M Hold
496,012
– – 5.23% 8
2022
Q1 		$9.17M Sell
496,012
-108,762
-18% -$2.09M 6.8% 6
2021
Q4 		$12M Sell
604,774
-300,204
-33% -$5.59M 4.18% 8
2021
Q3 		$14.9M Buy
904,978
+45,068
+5% +$661K 4.38% 9
2021
Q2 		$15.7M Buy
859,910
+179,142
+26% +$3.07M 3.91% 11
2021
Q1 		$11.4M Buy
+680,768
New +$12.7M 2.18% 13

Other funds holding VRDN

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ally Bridge Group's VRDN Position: Q3 2023 in Review

Ally Bridge Group sold out of Viridian Therapeutics (VRDN) in Q3 2023, closing a stake of 201,752 shares — an estimated $4.8M sold.

Ally Bridge Group first reported a position in VRDN in Q1 2021 and held it in 7 quarters. The position peaked at $15.7M in Q2 2021. 123 funds tracked by Wall St. Rank hold VRDN as of Q3 2023.

  • Ally Bridge Group reported no remaining Viridian Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ally Bridge Group sold 201,752 Viridian Therapeutics shares in Q3 2023, an estimated $4.8M.
  • Ally Bridge Group first reported a position in Viridian Therapeutics in Q1 2021 and held it in 7 quarters.
  • Ally Bridge Group's Viridian Therapeutics position peaked at $15.7M in Q2 2021.
  • 123 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2023.

Based on Ally Bridge Group's 13F filing for Q3 2023, filed 14 Nov 2023.